

Research article

Open Access

The candidate genes *TAF5L*, *TCF7*, *PDCDI*, *IL6* and *ICAM1* cannot be excluded from having effects in type I diabetes

Jason D Cooper¹, Deborah J Smyth¹, Rebecca Bailey¹, Felicity Payne^{1,2}, Kate Downes¹, Lisa M Godfrey¹, Jennifer Masters^{1,3}, Lauren R Zeitels¹, Adrian Vella^{1,4}, Neil M Walker¹ and John A Todd*¹

Address: ¹Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0XY, UK, ²Metabolic Disease Group, Sulston Laboratory, Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK, ³Division of Transfusion Medicine, Department of Haematology, University of Cambridge, East Anglia Blood Centre, Cambridge, CB2 2PT, UK and ⁴Mayo Clinic College of Medicine, Division of Endocrinology and Metabolism, 200 First ST SW, Rochester, MN55905, USA

Email: Jason D Cooper - jason.cooper@cimr.cam.ac.uk; Deborah J Smyth - deborah.smyth@cimr.cam.ac.uk; Rebecca Bailey - rebecca.bailey@cimr.cam.ac.uk; Felicity Payne - fp1@sanger.ac.uk; Kate Downes - kate.downes@cimr.cam.ac.uk; Lisa M Godfrey - lisa_monique18@hotmail.com; Jennifer Masters - jdm55@cam.ac.uk; Lauren R Zeitels - lzeitels@gmail.com; Adrian Vella - vella.Adrian@mayo.edu; Neil M Walker - neil.walker@cimr.cam.ac.uk; John A Todd* - john.todd@cimr.cam.ac.uk

* Corresponding author

Published: 28 November 2007

Received: 21 August 2007

BMC Medical Genetics 2007, 8:71 doi:10.1186/1471-2350-8-71

Accepted: 28 November 2007

This article is available from: <http://www.biomedcentral.com/1471-2350/8/71>

© 2007 Cooper et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: As genes associated with immune-mediated diseases have an increased prior probability of being associated with other immune-mediated diseases, we tested three such genes, *IL23R*, *IRF5* and *CD40*, for an association with type I diabetes. In addition, we tested seven genes, *TAF5L*, *PDCDI*, *TCF7*, *IL12B*, *IL6*, *ICAM1* and *TBX21*, with published marginal or inconsistent evidence of an association with type I diabetes.

Methods: We genotyped reported polymorphisms of the ten genes, nonsynonymous SNPs (nsSNPs) and, for the *IL12B* and *IL6* regions, tag SNPs in up to 7,888 case, 8,858 control and 3,142 parent-child trio samples. In addition, we analysed data from the Wellcome Trust Case Control Consortium genome-wide association study to determine whether there was any further evidence of an association in each gene region.

Results: We found some evidence of associations between type I diabetes and *TAF5L*, *PDCDI*, *TCF7* and *IL6* (ORs = 1.05 – 1.13; $P = 0.0291 – 4.16 \times 10^{-4}$). No evidence of an association was obtained for *IL12B*, *IRF5*, *IL23R*, *ICAM1*, *TBX21* and *CD40*, although there was some evidence of an association (OR = 1.10; $P = 0.0257$) from the genome-wide association study for the *ICAM1* region.

Conclusion: We failed to exclude the possibility of some effect in type I diabetes for *TAF5L*, *PDCDI*, *TCF7*, *IL6* and *ICAM1*. Additional studies, of these and other candidate genes, employing much larger sample sizes and analysis of additional polymorphisms in each gene and its flanking region will be required to ascertain their contributions to type I diabetes susceptibility.

Background

Type 1 diabetes is a chronic autoimmune disease with a complex pathogenesis involving multiple genetic and environmental factors. Before the advent of genome-wide association (GWA) studies, disease loci were primarily sought through the testing of candidate genes, selected based usually upon limited prior information about the function of the gene and the pathogenic mechanisms of disease. The candidate gene approach has been successful in finding disease loci, but as only relatively small numbers of genes have been studied, few true positive associations have been found, despite numerous studies and enormous effort [1]. Only five type 1 diabetes loci with compelling evidence had been identified before the advent of GWA studies: the HLA class II genes on chromosome 6p21 [2]; the insulin gene (*INS*) on 11p15 [3]; *CTLA4* on 2q33 [4]; *PTPN22* on 1q13 [5,6]; and, *IL2RA/CD25* on 10p15 [7,8]. Another five type 1 diabetes loci with convincing evidence have so far been identified by GWA studies in chromosome regions 2q24.3 [9], 12q24, 12q13, 16p13 and 18p11 [10,11].

Previously, we noted that, with the exception of *INS* [12], the type 1 diabetes loci contain polymorphisms that have been associated with susceptibility to other immune-mediated diseases, such as Graves' disease (GD) and systemic lupus erythematosus (SLE), suggesting the existence of shared disease loci [13]. In this study, we tested three genes, namely, *IL23R*, *IRF5* and *CD40*, which have been associated with other immune-mediated diseases (Table 1), including Crohn's disease (CD), psoriasis, SLE and GD, for an association with type 1 diabetes. In addition, we tested seven genes, namely, *ICAM1*, *TAF5L*, *PDCD1*, *TCF7*, *IL12B*, *IL6* and *TBX21*, with marginal or inconsistent evidence of an association with type 1 diabetes (Table 1). *PDCD1* has also been associated with SLE and Rheumatoid Arthritis (RA). We genotyped reported polymorphisms, nonsynonymous SNPs (nsSNPs) and tag SNPs for the *IL12B* and *IL6* regions in up to 7,888 case, 8,858 control and 3,142 parent-child trio samples. In addition, we used Wellcome Trust Case Control Consortium (WTCCC) [10] GWA study data to determine whether there was any further evidence of an association with type 1 diabetes in the linkage disequilibrium (LD) blocks containing the reported polymorphisms of interest.

Methods

Subjects

Type 1 diabetes families were white European or of white European descent, with two parents and at least one affected child comprising DNA samples from up to 918 Finnish multiplex/simplex families [14], 456 multiplex Diabetes UK Warren I families [15], 278 multiplex Human Biological Data Interchange (HBDI) families

[16], 80 Yorkshire simplex families, 263 Belfast multiplex/simplex [17], 360 Norwegian simplex families [18] and 240 Romanian simplex families [19]. The single SNPs from *TAF5L* and *IL12B*, two SNPs from *PDCD1* and five SNPs from *IL6* were genotyped in all the families. The *TCF7* SNP was genotyped in Warren, Yorkshire, Belfast and Romanian families. The *TBX21* SNP was genotyped in Warren, Yorkshire, HBDI, Belfast and Romanian families. The *CD40* SNP was genotyped in Warren and HBDI families.

The type 1 diabetes cases (maximum 7,888) [20], the British 1958 Birth Cohort (maximum 8,858) [21] and the UK Blood Services controls (1,500) have been described previously [6,10]. All cases and controls are white European. All DNA samples were collected after approval from the relevant research ethics committees and written informed consent was obtained from the participants.

Additional file 1, Table S1 contains a summary of the samples genotyped for each gene.

SNP identification and genotyping

IL12B is among the genes re-sequenced by the University of Washington: the Fred Hutchinson Cancer Research Centre (UW-FHCRC) Variation Discovery Resource [22]. The *IL12B* SeattleSNPs encompass the introns and exons between 1.7 kb 5' of exon 2 to 2 kb 3' of the untranslated exon 8 of *IL12B*. In this region, they detected 33 polymorphisms in their set of 23 DNA samples from Centre d'Etude du Polymorphisme Humain (CEPH) parents of European descent. As the untranslated exon 1 and 5' region beyond it were not sequenced, we re-sequenced, a further 2.9 kb 5', including exon 1 and the known promoter in the same 23 CEPH parents used by SeattleSNPs. This identified a further four polymorphisms including the CTCTAA/CG complex promoter deletion insertion (DIP) (rs17860508), incorrectly described previously as a 4 bp deletion [23].

IL6 was also resequenced by the SeattleSNP Project.

SNPs were genotyped using either Taqman MGB chemistry (Applied Biosystems) or Invader Bplex Assay (Third Wave Technologies, Madison). The D5S2941 microsatellite was genotyped using PCR and evaluated size differences using an ABI 3700 capillary sequencer.

Wellcome Trust Case Control Consortium

We used data from the WTCCC GWA study [10] to determine whether there was any evidence of an association with type 1 diabetes in the LD blocks containing the polymorphisms of interest. LD blocks were defined using Haploview [24] and HapMap Project [25] data for the 60 Centre d'Etude du Polymorphisme Humain (CEPH) par-

Table 1: Candidate genes and their previous associations.

Gene and polymorphism	Candidacy	Previous disease associations
<i>TAF5L</i> on 1q42 C744A (rs3753886)	<i>TAF5L</i> encodes a protein that is a component of the PCAF histone acetylase complex. It may participate in basal transcription, serve as a coactivator, function in promoter recognition or modify general transcription factors to facilitate complex assembly and transcription initiation.	T1D: <ul style="list-style-type: none"> Chistiakov <i>et al</i> [35] 247 Russian cases and 258 controls, derived OR for C allele = 0.69 (0.52–0.92), $P = 0.013$.
<i>PDCD1</i> on 2q37 7146G>A (rs11568821) 872C>T (rs2227981)	Belongs to the B7-CD28 superfamily. These molecules play a critical role in the development of the immune response by controlling T cell numbers, through a fine balance of stimulation and negative regulation, which is essential for the prevention of autoimmunity.	SLE, RA and T1D: <ul style="list-style-type: none"> Prokunina <i>et al</i> [58] SLE: 7146G>A: 443 families and 520 cases of European, Mexican and African-American descent, RR for A allele = 2.6 (1.6–4.4), $P = 1.0 \times 10^{-5}$ for Europeans and RR for A allele = 3.5 (1.4–8.5), $P = 9.0 \times 10^{-4}$ for Mexicans. Prokunina <i>et al</i> [37] RA: 7146G>A: 1,175 cases and 3,404 controls, OR for A allele = 1.18 (0.99–1.41), $P = 0.05$. Lin <i>et al</i> [59] 872C>T: 98 SLE cases and 100 controls, 84 RA cases and 135 controls, OR for T allele = 3.32 (1.78–6.21), $P < 0.0001$, no association in SLE. Nielsen <i>et al</i> [36] T1D:7146G>A: 192 Danish cases and 155 controls, OR for A allele = 1.92 (1.1–3.3), $P = 0.02$.
<i>TCF7</i> on 5q31 Pro19Thr (rs5742913)	Role as a transcription factor in regulating key immune response elements and its involvement in T-cell development in the thymus.	T1D: <ul style="list-style-type: none"> Noble <i>et al</i> [38] 282 USA families, RR = 1.21, $P_{TDT} = 0.12$. A allele transmitted from fathers, RR = 1.79, $P_{TDT} = 0.007$, $P_{ESP} = 0.03$. To male offspring, $P_{ESP} = 0.04$. To low HLA risk (non DR3/DR4) offspring, RR = 1.35, $P_{TDT} = 0.06$, $P_{ESP} = 0.04$. Early onset offspring, $P_{ESP} = 0.09$.
<i>IL12B</i> on 5q33.3 A1159C (rs3212227) Microsatellite D5S2941	This gene, encoding the p40 subunit of IL-12, drives the differentiation of T lymphocytes into the Th1 subset, which is characterized by the production of cytokines that promote cell-mediated immunity.	T1D: <ul style="list-style-type: none"> Morahan <i>et al</i> [49] 249 Eastern Australian multiplex families, RR for A allele = 1.40 (1.11–1.77), $P = 0.0025$. 235 Australian simplex families, RR for A allele = 1.84 (1.32–2.56), $P = 0.00014$. Davoodi-Sermiromi <i>et al</i> [41] 364 USA multiplex families, RR for C allele = 1.23 (0.97–1.56), $P = 0.08$. haplotype: allele 2 (D5S2941) and I159C, $P = 0.02$. Windsor <i>et al</i> [40] 648 cases and 246 controls – Western Australia, OR allele C = 1.6 (1.2–2.0), $P = 0.001$. Excess of heterozygotes in cases ≥ 16 yrs diagnosis, OR = 1.8 (1.2–2.7), $P = 0.005$ and ≥ 26 yrs diagnosis, OR = 2.4 (1.5–3.8), $P = 0.0002$. Five studies failed to find an association: <ul style="list-style-type: none"> Dahlman <i>et al</i> [60] 2,873 families from UK, USA, Finland, Romania McCormack <i>et al</i> [61] 120 cases, 330 controls and 307 families from Northern Ireland Nistico <i>et al</i> [62] 470 cases and 544 controls from Italy. Bergholdt <i>et al</i> [63] 337 Danish simplex and 795 European and American multiplex families. Johansson <i>et al</i> [64] from Norway.
<i>IL6</i> on 7p21 174G>C (rs1800795)	<i>IL6</i> may contribute to the gradual destruction of the pancreatic beta cells, due to its regulatory role in inflammation and the immune response.	T1D: <ul style="list-style-type: none"> Kristiansen <i>et al</i> [43] 253 Danish families, RR allele C = 1.26 (1.01–1.57), $P_{TDT} = 0.04$. Parent-female-trios: RR for C allele = 1.72 (1.25–2.36), $P = 6.5 \times 10^{-4}$. Parent-male-trios: RR for C allele = 0.91 (0.67–1.24), $P = 0.58$. Age-at-onset males = 14.04 yrs (11.62–16.46) and females = 8.81 yrs (6.60–11.01), interaction model $P = 0.002$. Gillespie <i>et al</i> [44] UK 1,230 cases. <i>IL6-174CC</i> less frequent in females diagnosed after, than in those diagnosed before, 10 years, $P = 0.016$. Jahromi <i>et al</i> [65] 257 cases and 120 newborn controls, UK, OR for C allele = 0.54 (0.39–0.74), derived $P = 7.8 \times 10^{-5}$. 53 parent-child trios RR for C allele = 0.83 (0.48–1.43) Eerligh <i>et al</i> [66] 206 Dutch simplex families, no association.

Table 1: Candidate genes and their previous associations. (Continued)

<p><i>ICAM1</i> on 19p13 G241R (rs1799969)</p>	<p><i>ICAM-1</i>, upregulated during inflammation and hyperglycemia, is involved in the attachment of lymphocytes to the endothelium as well as in the priming of effector T cells.</p>	<p>T1D: Kristiansen <i>et al.</i> [45] 253 Danish families, no association with K469E. Nejentsev <i>et al.</i> [67] 3,695 families from Finland, UK, USA, Norway & Romania, RR = 0.91 (0.83–0.99) $P = 0.030$. 446 families from Bart's-Oxford study RR = 0.60 (0.40–0.89) $P = 0.006$. Ma <i>et al.</i> [68] 432 cases and 187 controls from Sweden. Tested five SNPs, rs281432 and rs5498 had P-values of 0.026 and <0.001 respectively when genotype model assumed.</p>
<p><i>TBX21</i> on 17q21 His33Gln (rs2240017)</p>	<p><i>TBX21</i> has a role in the complex regulation of T lymphocyte responses, as a master-regulator of Th1 cytokine IFN-γ gene expression.</p>	<p>T1D: ▪ Sasaki <i>et al.</i> [46], 153 cases and 200 controls from Japan, OR for G allele = 1.77 (1.08–2.91), $P = 0.02$.</p>
<p><i>IL23R</i> on 1p31 Arg381Gln (rs11209026)</p>	<p>The protein encoded pairs with the receptor molecule <i>IL12RB1/IL12Rbeta1</i>, and both are required for <i>IL23A</i> signaling. This protein associates constitutively with Janus kinase 2 (<i>JAK2</i>), and also binds to transcription activator <i>STAT3</i> in a ligand-dependent manner.</p>	<p>IBD and psoriasis: ▪ Duerr <i>et al.</i> [69] CD: 547 non-Jewish cases and 548 controls, OR = 0.26 (0.15–0.43), $P = 5.05 \times 10^{-9}$. 401 Jewish cases and 433 controls, OR = 0.45 (0.27–0.73), $P = 7.95 \times 10^{-4}$. 883 IBD families, $P = 1.32 \times 10^{-10}$. ▪ Cargill <i>et al.</i> [54] Psoriasis: White North American 1446 cases and 1432 controls, OR = 0.63 (0.50–0.79), $P = 1.89 \times 10^{-4}$.</p>
<p><i>IRF5</i> on 7q32.1 -3835 (rs2004640)</p>	<p>Member of a family of transcriptional factors that controls inflammatory and immune responses.</p>	<p>SLE: ▪ Sigurdsson <i>et al.</i> [70], 679 cases and 438 controls from Sweden, Finland and Iceland, $P = 2.4 \times 10^{-7}$. ▪ Graham <i>et al.</i> [71] 1,661 cases and 2,508 controls from USA, Spain, Sweden and Argentina, OR = 1.47 (1.36–1.60), $P = 4.2 \times 10^{-21}$. T1D: One study failed to find an association. Qu <i>et al.</i> [72] 947 T1D families.</p>
<p><i>CD40</i> on 20q12 Kozak (rs1883832)</p>	<p><i>CD40</i> and <i>CD40L</i> signalling is known to play an important role in the immune response. The proteins are expressed in a variety of cell types and ligation causes cells to produce inflammatory cytokines and cellular adhesion molecules.</p>	<p>GD: ▪ Tomer <i>et al.</i> [48] 154 cases and 118 controls – Caucasian, OR for CC genotype = 1.6, $P = 0.048$. ▪ Kim <i>et al.</i> [73] 132 cases and 164 controls from Korea, OR for CC genotype = 1.93 (1.21–3.09), $P = 0.019$. ▪ Mukai <i>et al.</i> [74] 324 cases and 229 controls from Japan: late onset GD, decrease in TT allele ($P = 0.011$) Two studies failed to find an association: ▪ Houston <i>et al.</i> [75] 451 cases and 446 controls from UK. ▪ Heward <i>et al.</i> [76] 800 cases and 785 controls from UK.</p>

T1D = type 1 diabetes, SLE = systemic lupus erythematosus, RA = Rheumatoid Arthritis, IBD = Inflammatory Bowel disease, CD = Crohn's disease and GD = Graves' disease.

ents. We used the four gamete rule [26] for defining LD blocks within Haploview. We note that the 2,000 case and 3,000 (1,500 from the British 1958 Birth Cohort and 1,500 from the UK Blood Services) control samples used by the WTCCC where also genotyped in this study. We required WTCCC SNPs to have a minor allele frequency (MAF) ≥ 0.05 , a call rate ≥ 0.99 and no extreme deviation from Hardy-Weinberg equilibrium (HWE) ($\chi_1^2 \leq 25$) [27].

Statistical Analysis

All statistical analyses were performed in either Stata [28] or R [29] statistical systems. Additional routines may be downloaded [30].

All unaffected parent and control genotypes were assessed for, and found to be in Hardy-Weinberg equilibrium ($P > 0.05$). SNPs genotyped in the family collection were analysed using the transmission/disequilibrium test [31] and, after estimating pseudo-controls [32], conditional logistic regression, respectively modelling allelic relative risks (RRs; a one-degree-of-freedom (df) test) and genotype RRs (a two-df test). In the case and pseudo-control analysis, we consider the transmitted pair of alleles as the "case" and the other three possible pairs of transmitted alleles as "pseudo-controls" in a matched case-control study [32]. The one-df test assumes multiplicative allelic effects and the two-df test assumes no specific mode of inheritance, for example, in the analysis of TCF7 C883A, genotype risks of C/A and A/A were modelled relative to the C/C genotype.

In the case-control collection, we performed similar tests using logistic regression models, stratified by 12 broad geographical regions (Southwestern; Southern; Southeastern; London; Eastern; Wales; Midlands; North Midlands; Northwestern; East and West Riding; Northern; and, Scotland), to allow for geographic variation in allele frequencies across Great Britain [27].

The tag SNPs were selected and analysed using a multilocus test, as previously described [7,33]. Qu *et al.* [8] recently reported that the family-based multilocus test was not confined to heterozygous parents, which compromised the protection against population stratification. This is incorrect, as described in the studies by Chapman *et al.* [33] and Lowe *et al.* [34], only transmissions from heterozygous parents contribute to the test.

Results

TAF5L

We genotyped one TAF5L SNP (C744A; rs3753886), which has previously been associated with type 1 diabetes [35] (Table 1). We found inconsistent evidence of an association between type 1 diabetes and C744A in the case-control and family collections. In 7,497 case and 7,496

control genotypes, we obtained marginal evidence of an association ($P = 7.32 \times 10^{-3}$; OR for allele A = 1.07, 95% CI 1.02–1.12; Table 2). Although, in 2,645 parent-child trio genotypes, there was borderline evidence of an association ($P = 0.0519$), the risk for the minor allele (RR for allele A = 0.92, 95% CI 0.85–0.99; Table 3) was going in the opposite direction to that in the case-control collection.

We found borderline evidence of an association in the WTCCC, which had two SNPs with a MAF ≥ 0.05 in the 5 kb LD block containing C744A. The lowest P -value was for C744A ($P = 0.0561$).

PDCD1

We genotyped two PDCD1 SNPs (7146G>A and 872C>T), which have previously been associated with type 1 diabetes [36] and RA respectively [37] (Table 1). We found inconsistent evidence of an association between type 1 diabetes and 7146G>A in the case-control and family collections (Tables 2 and 3). In 7,888 case and 8,858 control genotypes, we obtained limited evidence of an association ($P = 0.0102$; OR for allele A = 1.10, 95% CI = 1.02–1.17). In 3,125 parent-child trio genotypes, no evidence of an association was found ($P = 0.498$). For the second SNP, 872C>T, no evidence of an association was found in either collection (Tables 2 and 3).

There were no WTCCC SNPs with a MAF ≥ 0.05 in the 12 kb LD block containing 7146G>A. We note that 7146G>A was not included in either HapMap or the WTCCC study.

TCF7

We genotyped one TCF7 SNP (C883A; rs5742913), which had previously been associated with type 1 diabetes [38] (Table 1). Despite obtaining no evidence of an overall association, Noble *et al.* [38] proceeded to analyse subgroups, defined by up to three criteria, in which they found an excess of the A allele transmitted: from fathers; to male offspring; to low HLA risk (non-DR3/DR4) offspring; and, to early onset offspring (Table 1). We found some evidence of an association between type 1 diabetes and C883A in the case-control and family collections (Tables 2 and 3). In 7,434 case and 8,637 control genotypes, in contrast to Noble *et al.* [38], we obtained evidence of an association with type 1 diabetes ($P = 4.16 \times 10^{-4}$; OR for allele A = 1.13, 95% CI = 1.06–1.22). In 1,556 parent-child trio genotypes, no evidence of an association was found ($P = 0.608$). In addition, we found no evidence of an association between type 1 diabetes and C883A when comparable subgroup analyses, as described by Noble *et al.* [38], were performed (see Additional file 1, Table S2). We also performed, a case-only regression analysis of cases and affected offspring from the case-control and family collections respectively, which showed no con-

Table 2: Association analyses in type I diabetes cases and controls.

		Alleles			Genotypes		
<i>TAF5L</i>	C744A (rs3753886)	C	A	CC	CA	AA	
	7,497 cases 7,496 controls OR (95% CI) P	7,457 (49.7) 7,671 (51.2) 1.00 (reference)	7,537 (50.3) 7,321 (48.8) 1.07 (1.02–1.12) 7.32×10^{-3}	1,827 (24.4) 1,928 (25.7) 1.00 (reference)	3,803 (50.7) 3,815 (50.9) 1.05 (0.97–1.14)	1,867 (24.9) 1,753 (23.4) 1.14 (1.04–1.25)	0.0244
<i>PDCD1</i>	7146G>A (rs11568821)	G	A	GG	GA	AA	
	7,888 cases 8,858 controls OR (95% CI) P	13,966 (88.3) 15,846 (88.5) 1.00 (reference)	1,810 (11.7) 1,870 (11.5) 1.10 (1.02–1.17) 0.0102	6,196 (78.6) 7,088 (80.0) 1.00 (reference)	1,574 (20.0) 1,670 (18.9) 1.08 (1.00–1.17)	118 (1.5) 100 (1.1) 1.32 (1.00–1.74)	0.0268
<i>PDCD1</i>	872C>T (rs2227981)	C	T	CC	CT	TT	
	5,758 cases 7,289 controls OR (95% CI) P	6,699 (58.2) 8,440 (57.9) 1.00 (reference)	4,817 (41.8) 6,138 (42.1) 1.00 (0.95–1.06) 0.586	1,956 (34.0) 2,461 (33.8) 1.00 (reference)	2,787 (48.4) 3,518 (48.3) 1.00 (0.92–1.08)	1,015 (17.6) 1,310 (18.0) 0.97 (0.87–1.07)	0.760
<i>TCF7</i>	Pro19Thr (rs5742913)	C	A	CC	CA	AA	
	7,434 cases 8,637 controls OR (95% CI) P	13,022 (87.6) 15,355 (88.9) 1.00 (reference)	1,846 (12.4) 1,919 (11.1) 1.13 (1.06–1.22) 4.16×10^{-4}	5,709 (76.8) 6,826 (79.0) 1.00 (reference)	1,604 (21.6) 1,703 (19.7) 1.13 (1.04–1.22)	121 (1.6) 108 (1.3) 1.32 (1.01–1.73)	1.91×10^{-3}
<i>IL12B</i>	A1159C (rs3212227)	A	C	AA	AC	CC	
	4,321 cases 4,711 controls OR (95% CI) P	6,898 (79.8) 7,588 (80.5) 1.00 (reference)	1,744 (20.2) 1,834 (19.5) 1.06 (0.98–1.14) 0.134	2,748 (63.6) 3,050 (64.7) 1.00 (reference)	1,402 (32.5) 1,488 (31.6) 1.06 (0.96–1.16)	171 (4.0) 173 (3.7) 1.13 (0.90–1.42)	0.324
<i>IL6</i>	174G>C (rs1800795)	G	C	GG	GC	CC	
	7,785 cases 8,852 controls OR (95% CI) P	8,726 (56.0) 10,168 (57.4) 1.00 (reference)	6,844 (44.0) 7,536 (42.6) 1.05 (1.01–1.10) 0.0291	2,928 (33.1) 2,456 (31.6) 1.00 (reference)	4,312 (48.7) 3,814 (49.0) 1.04 (0.97–1.12)	1,612 (18.2) 1,515 (19.5) 1.11 (1.01–1.21)	0.0879

Table 2: Association analyses in type I diabetes cases and controls. (Continued)

<i>ICAM1</i>	G241R (rs1799969)	G	A	GG	GA	AA
		10,257 (88.8)	1,295 (11.2)	4,553 (78.8)	1,151 (19.9)	72 (1.3)
		10,787 (88.5)	1,401 (11.5)	4,787 (78.6)	1,213 (19.9)	94 (1.54)
		1.00 (reference)	0.96 (0.89–1.05)	1.00 (reference)	1.00 (0.91–1.10)	0.74 (0.54–1.02)
			0.382			0.179
<i>TBX21</i>	His33Gln (rs2240017)	C	G	CC	CG	GG
		8,456 (97.4)	228 (2.6)	4,116 (94.8)	224 (5.2)	2 (0.1)
		9,293 (97.6)	233 (2.4)	4,533 (95.2)	227 (4.7)	3 (0.1)
		1.00 (reference)	1.08 (0.89–1.30)	1.00 (reference)	1.08 (0.88–1.31)	1.10 (0.16–7.54)
			0.459			0.759
<i>IL23R</i>	Arg381Gln (rs11209026)	G	A	GG	GA	AA
		11,413 (93.7)	761 (6.3)	5,343 (87.8)	727 (11.9)	17 (0.3)
		11,776 (93.4)	830 (6.6)	5,499 (87.2)	778 (12.3)	26 (0.4)
		1.00 (reference)	0.93 (0.84–1.03)	1.00 (reference)	0.95 (0.85–1.06)	0.67 (0.36–1.26)
			0.183			0.285
<i>IRF5</i>	-3835 (rs2004640)	T	G	TT	TG	GG
		5,834 (51.6)	5,480 (48.4)	1,487 (26.3)	2,860 (50.6)	1,310 (23.2)
		6,160 (51.0)	5,928 (49.0)	1,581 (26.2)	2,998 (49.6)	1,465 (24.2)
		1.00 (reference)	0.98 (0.93–1.03)	1.00 (reference)	1.03 (0.94–1.12)	0.96 (0.86–1.06)
			0.451			0.353
<i>CD40</i>	Kozak (rs1883832)	C	T	CC	CT	TT
		6,624 (75.4)	2,160 (24.6)	2,500 (56.9)	1,624 (37.0)	268 (6.1)
		7,132 (75.8)	2,272 (24.2)	2,680 (57.0)	1,772 (37.7)	250 (5.3)
		1.00 (reference)	1.03 (0.96–1.10)	1.00 (reference)	0.97 (0.89–1.07)	1.18 (0.97–1.42)
			0.456			0.162

OR = odds ratio for the minor allele, 95% CI = 95% confidence interval.

Table 3: Association analyses in type 1 diabetes families.

		Parent-child-trios (families)	Parental MAF	Transmission/disequilibrium test			
				Minor allele		RR (95% CI)	P
				Transmitted	Untransmitted		
TAF5L	A1159C (rs3212227)	2,645 (2,515)	46.8	1,299	1,400	0.92 (0.85–0.99)	0.0519
PDCD1	7146G>A (rs11568821)	3,125 (2,742)	9.3	516	538	0.96 (0.85–1.08)	0.498
PDCD1	872C>T (rs2227981)	2,190 (1,831)	42.5	1,111	1,043	1.07 (0.98–1.16)	0.143
TCF7	C883A (rs5742913)	1,556 (1,224)	11.2	327	314	1.04 (0.89–1.21)	0.608
IL12B	A1159C (rs3212227)	3,015 (2,606)	18.9	949	933	1.02 (0.93–1.12)	0.712
IL6	174G>C (rs1800795)	2,803 (2,651)	47.0	1,411	1,360	1.04 (0.97–1.12)	0.333
TBX21	His33Gln (rs2240017)	1,989 (1,374)	2.7	111	100	1.11 (0.85–1.45)	0.449
CD40	Kozak (rs1883832)	1,446 (795)	24.1	522	542	0.96 (0.85–1.08)	0.540

MAF = minor allele frequency, RR = relative risk for minor allele, 95% CI = 95% confidence interval.

sistent evidence of a gender or age-at-diagnosis effect at C883A. Similarly, a case-only gene-gene interaction analysis between C883A and the known type 1 diabetes loci, *HLA*, *INS*, *CTLA4* and *PTPN22*, revealed no consistent evidence of an interaction with C883A (see Additional file 1, Table S3). We note that the lack of evidence for an interaction between C883A and *PTPN22* 1858C>T contradicts a previous study reporting an over-transmission of *PTPN22* 1858T to individuals who have at least one copy of *TCF7* 883A ($P = 0.015$) [39].

We found no evidence of an association in the WTCCC, which had two SNPs with a MAF ≥ 0.05 in the 66 kb LD block containing C883A. The SNP with the lowest P -value was rs756699 ($P = 0.694$). We note that C883A was not included in either HapMap or the WTCCC study.

IL12B

IL12B has been reported to be associated with type 1 diabetes in some but not all studies (Table 1). Therefore, we investigated the contribution of *IL12B* to type 1 diabetes susceptibility, as thoroughly as possible, by genotyping a SNP (A1159C; rs3212227), two rare nsSNPs (rs3213096 and rs3213119), a microsatellite (D5S2941) and a set of tag SNPs for the *IL12B* region. In 4,321 case, 4,711 control and 3,015 parent-child genotypes, we obtained no evidence of an association between type 1 diabetes and A1159C ($P = 0.134$ and 0.630 respectively; Tables 2 and 3). In addition, we performed a case-only analysis to replicate the association reported by Windsor *et al.* [40] between A1159C and age-at-diagnosis (Table 1). However, no evidence of an age-at-diagnosis effect at A1159C was found (see Additional file 1, Table S4).

The microsatellite D5S2941, in *IL12B* intron 2, had previously been reported to be associated with type 1 diabetes by Davoodi-Semiromi *et al.* [41] ($P < 0.006$; Table 1).

They detected two alleles, a major allele 1 with eight repeat units and a minor allele 2 with nine repeat units, and found over-transmission of allele 2 to affected offspring. We detected an additional two, extremely rare, alleles: allele 3 (ten repeat units) and allele 4 (seven repeat units), both found at frequency of <0.001 . In 1,327 case and 1,160 control genotypes, we obtained no evidence of an association between type 1 diabetes and D5S2941 allele 2 ($P = 0.114$). Davoodi-Semiromi *et al.* also reported an association between type 1 diabetes and the D5S2941 allele 2-1159C haplotype ($P = 0.02$) and suggested the possibility that the causal variant remained ungenotyped and elsewhere in *IL12B* [41]. Consequently, we also analysed this haplotype using an EM algorithm-based routine to assign haplotypes to cases and controls, which were then analysed using a linear model weighted by the posterior haplotype probabilities for each case or control. Again we found no association with disease for this haplotype in 1,298 case and 1,111 control genotypes ($P = 0.195$).

To investigate the possibility of a polymorphism associated with type 1 diabetes in *IL12B* that we, or others, have not yet genotyped, we adopted an linkage disequilibrium (LD) mapping approach using tag SNPs (Table 4). We combined resequencing data in 23 CEPH parents from the SeattleSNP project [22] with inhouse resequencing of the untranslated exon 1 and 5', not resequenced in the SeattleSNP project (Methods). In the combined resequencing data, we identified 38 polymorphisms, comprising 34 SNPs (four SNPs provided by the in house resequencing), three deletion-insertion polymorphisms (DIPs) and the microsatellite D5S2941 (see Additional file 1, Table S5). Six tag SNPs were selected (minimum $R^2 = 0.80$) from 25 SNPs with a minor allele frequency (MAF) ≥ 0.10 . The set of tag SNPs was genotyped in the case-control collection and analysed using a multilocus test, which tests for an association between type 1 diabetes and the tag SNPs due

Table 4: Tag SNP results for *IL6* and *IL12B* regions.

	Exons	Sequencing source	Polyorphisms	Tag SNPs	Multilocus test <i>P</i> -values	
					Families	Cases and controls
<i>IL12B</i>	8	Seattle SNPs and in house (23 subjects)	33 (from Seattle) 4 (in house) 25 had a MAF \geq 0.10	6	N/A	0.940 1,590 cases and 1,748 controls
<i>IL6</i>	6	Seattle SNPs (23 subjects)	49 12 had MAF \geq 0.10	4	0.0231 3,320 parent-child trios	0.236 3,486 cases and 3,783 controls

We selected tag SNPs from SNPs with a MAF \geq 0.10. MAF = minor allele frequency.

to LD with one or more causal variants [33]. The multilocus test *P*-value was 0.940, providing no evidence of an association between type 1 diabetes and the *IL12B* region (Table 4). We note that rs17860508, the promoter DIP CTCTAA/CG, was selected as a tag SNP. Previously, this polymorphism had been associated with asthma susceptibility [23] and IgE levels [42], but we found no association with type 1 diabetes (4,367 case and 4,714 control genotypes, *P* = 0.878).

Finally, we tested for an association between type 1 diabetes and two rare nsSNPs (rs3213096 and rs3213119). Although the MAF was 0.022 for both nsSNPs in the SeattleSNPs CEPH sequencing panel, in the case-control collection, rs321096 had a much lower MAF of 0.0035 in controls and consequently, we had no power in a collection of 4,383 case and 4,732 control genotypes to test for an association. The other nsSNP, rs3213199, with MAF of 0.034 in controls, showed no evidence of an association with type 1 diabetes in 4,348 case and 4,691 control genotypes (*P* = 0.0941).

We found limited evidence of an association in the WTCCC, which had six SNPs with a MAF \geq 0.05 in the 14 kb LD block containing A1159C. The only associated SNP was rs6859018 (*P* = 0.0274), which is in perfect LD (r^2 = 1) with A1159C in 60 CEPH parents. Consequently, based on the perfect LD between rs6859018 and A1159C, we can conclude that this association is a false positive. We note that A1159C was not included in the WTCCC study.

IL6

As *IL6* has been reported to be associated with type 1 diabetes [43] (Table 1), we sought to replicate this association by genotyping *IL6-174G>C* (rs1800795) and a set of tag SNPs for the *IL6* region. We found inconsistent evidence of an association between type 1 diabetes and *IL6-174G>C* in the case-control and family collections (Tables 2 and 3). In 7,785 case and 8,852 control genotypes, we obtained limited evidence of an association with type 1 diabetes (*P* = 0.0291; OR for allele C = 1.05, 95% CI =

1.01–1.10). In 2,803 parent-child trio genotypes, no evidence of an association was found (*P* = 0.333). As Kristiansen *et al.* [43] found evidence that the *IL6-174C* allele was only associated with type 1 diabetes in female offspring (Table 1), we analysed *IL6-174G>C* by sex. In the cases and controls, we obtained limited evidence of an association in males (*P* = 0.0378), but not in females (see Additional file 1, Table S6a) and in the families, we found no evidence of an association in either male or female type 1 diabetes offspring (see Additional file 1, Table S6b).

Previously, Gillespie *et al.* [44] found frequency differences in *IL6-174G>C* genotypes between males and females diagnosed ages > 10 years. Consequently, we conducted a similar case-only analysis using a multinomial logistic regression model to adjust for broad geographical region within Great Britain and for population of the cases and affected offspring, respectively. We found no evidence of genotype differences between 5,700 male and 5,292 female cases and affected offspring (*P* = 0.370) and when analysed by age-at-diagnosis (see Additional file 1, Table S7).

To test for an association between type 1 diabetes and the *IL6* region, we adopted a LD mapping approach. We used SeattleSNP resequencing data in 23 CEPH parents, four tag SNPs were selected (minimum R^2 = 0.80) from twelve SNPs with a MAF \geq 0.10 (see Additional file 1, Table S8). We found no evidence for association in the case-control collection (multilocus test *P* = 0.236). However, in the family collection, limited evidence of an association was found (multilocus test *P* = 0.0231) (Table 4).

We found no evidence of an association in the WTCCC, which had two SNPs with a MAF \geq 0.05 in the 4 kb LD block containing *IL6-174G>C*. The SNP with the lowest *P*-value was rs2069835 (*P* = 0.343). We note that *IL6-174G>C* was included in the WTCCC study, but was dropped as the call rate was below 0.99.

ICAM1

We genotyped one *ICAM1* SNP (G241R; rs1799969), which has previously been associated with type 1 diabetes [45] (Table 1). However, no evidence of an association was found in 5,776 cases and 6,094 controls ($P = 0.382$; Table 2).

We found some evidence of an association in the WTCCC, which had two SNPs with a $MAF \geq 0.05$ in the 15 kb LD block containing G241R. The most associated SNP was rs892188 ($P = 0.0257$; OR for allele T = 1.10, 95% CI = 1.01–1.19), located just over 2 kb upstream of the 3' UTR of *ICAM5*, which has low LD ($r^2 = 0.274$) with G241R. We note that G241R was not included in the WTCCC study.

TBX21

We genotyped one *TBX21* SNP (His33Gln; rs2240017), which had previously been associated with type 1 diabetes in a Japanese case and control collection [46] (Table 1). No evidence for association in either collection was found (Tables 2 and 3). We note that the G (Gln) allele frequency in controls was 0.024 (Table 2) and in parents 0.027, considerably lower than reported in Japanese by Sasaki *et al.* ($MAF = 0.105$) [46], but similar to that found in other European populations ($MAF = 0.030$) [47].

We found no evidence of an association in the WTCCC, which had one SNP with a $MAF \geq 0.05$ in the 14 kb LD block containing His33Gln. The SNP, rs2240017, had a P -value of 0.131. We note that His33Gln was not included in the WTCCC study.

IL23R

We genotyped one *IL23R* SNP (Arg381Gln; rs11209026), which has previously been associated with IBD and psoriasis (Table 1). In 6,087 cases and 6,303 controls, we found no evidence of an association with type 1 diabetes ($P = 0.183$; Table 2).

The only WTCCC SNP with a $MAF \geq 0.05$ in a 15 kb LD block containing Arg381Gln was Arg381Gln ($P = 0.857$).

IRF5 and CD40

We genotyped two SNPs from *IRF5* and *CD40* (-3835/rs2004640 and 168A>G/rs1883832, respectively), which have previously been associated with SLE and GD respectively (Table 1). The *CD40* -168A>G SNP has been reported to disrupt the Kozak consensus sequence necessary for efficient translation [48]. No evidence of an association was found for either SNP (Tables 2 and 3).

We found no evidence of an association in the WTCCC, which had no SNPs with a $MAF \geq 0.05$ in the 5 kb LD block containing -3835 and 168A>G was not contained

within a block. Neither -3835 nor 168A>G were included in the WTCCC study.

Discussion

In this study, we have tested ten candidate genes for an association with type 1 diabetes using large case-control and family collections. We did obtain some evidence, albeit inconsistent between collections, of an association with *TAF5L* (C744A), *PDCD1* (7146G>A), *TCF7* (C883A) and *IL6* (*IL6-174G>C*, rs2069849 and the *IL6* region). Although *TAF5L* (C744A; rs3753886), *PDCD1* (7146G>A; rs11568821), *TCF7* (C883A; rs5742913) and *IL6* (*IL6-174G>C*; rs1800795) have previously been associated with type 1 diabetes, the possibility remains that these associations are false positives. However, the findings reported here maybe the result of the case-control collection having more power than the family collection to detect SNPs with relatively small effects in type 1 diabetes or being in weak LD with the causal locus. Consequently, additional studies will be required to ascertain the contribution of *TAF5L*, *PDCD1*, *TCF7* and *IL6* to type 1 diabetes susceptibility. The case-control collection (8,000 cases and 8,000 controls) provided about 60% power to detect an OR of 1.2 for a MAF of 0.10 at a P -value of about 1×10^{-6} ; and about 96% power for a MAF of 0.20. The family collection (3,125 parent-child trios) provided less power to detect an OR of 1.2, after increasing the P -value to 1×10^{-3} , there was about 45.1% power for a MAF of 0.10 and about 81.4% power for a MAF of 0.20.

We did not obtain any evidence of an association between type 1 diabetes and either *ICAM1*, *IL12B* or *TBX21*, all of which had previously been associated with type 1 diabetes [45,46,49]. However, limited evidence of an association with rs892188, located in the LD block containing the reported SNP in *ICAM1*, was provided by the WTCCC. Additional studies will be required to ascertain the contribution of rs892188 to type 1 diabetes susceptibility. The previous reports of disease associations may well have been false positives, which have to be expected given: the low prior probability, even for candidate genes [1,50], of detecting a true causal locus of complex disease; the frequent use of relatively small sample sizes and of nominal levels of significance; and, the large numbers of SNPs tested for an association with type 1 diabetes. It is interesting to note that when, by chance, a true positive result is found, as in the case for *PTPN22* Arg620Trp SNP in type 1 diabetes [5], it is replicated by many groups, very rapidly [6,39,51,52], although this has a large effect approaching an OR = 2.

Finally, we did not obtain any evidence of an association between type 1 diabetes and *IL23R*, *IRF5* or *CD40*, all of which have previously been associated with other immune-mediated diseases including, most recently,

IL23R in Crohn's disease [10,53] and in psoriasis [54]. Lack of association of *IL23R*, *IRF5* and *CD40* with type 1 diabetes helps to delineate pathogenic mechanisms between type 1 diabetes and other immune-mediated diseases, especially when the associations reported for the other diseases are highly likely to be true positive results. Nevertheless, for these and other loci, it is possible that one or more of these genes could have allelic heterogeneity in which one allele predisposes to certain autoimmune diseases and a second allele at a different location in the gene predisposes to another. This possibility necessitates the continued investigation of further polymorphisms within each gene.

Conclusion

The functional candidate gene approach has now been superseded by GWA studies, which are detecting major susceptibility loci [10,11,53,55]. Most of the confirmed loci from GWA studies have ORs ≤ 1.3 , consistent with an L-shaped distribution of allelic effect sizes (that is, a small number of genes with large effects and a large number of genes with small effects) [1,11]. *TAF5L*, *PDCD1*, *TCF7*, *IL6* and *ICAM1* may be amongst the numerous loci with small effects in type 1 diabetes. We note that genes found with small effects on disease may have much larger effects in subgroups of phenotypically defined cases. For example, *CTLA4* genotypes has a small effect overall in type 1 diabetes (OR = 1.20, 95% CI 1.13–1.27), but subclassification of cases with or without the thyroid peroxidase autoantibodies revealed an increased effect (OR = 1.49, 95% CI 1.29–1.72) for cases with autoantibodies (without autoantibodies OR = 1.16, 95% CI 1.10–1.24) [56].

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

JDC contributed to data analysis and drafted the manuscript. DJS drafted the manuscript and worked on *IL23R*, *IRF5* and *CD40* studies. RB drafted the manuscript and worked on *TCF7* and *TBX21* studies. FP drafted the manuscript and worked on the *IL12B* study. KD worked on the *TAF5L* study. LMG drafted the manuscript and worked on the *IL6* study. JM drafted the manuscript and worked on the *PDCD1* study. LRZ worked on *PDCD1*, *TCF7* and *ICAM1* studies. AV drafted the manuscript and worked on the *TCF7* study. NMW managed the data. JAT participated in the conception, design and coordination of the studies, data analysis and drafted the manuscript. All authors read and approved the final manuscript.

Additional material

Additional file 1

Supplementary Tables. Summary tables of additional analyses conducted.

Click here for file

[http://www.biomedcentral.com/content/supplementary/1471-2350-8-71-S1.doc]

Acknowledgements

This work was funded by the Wellcome Trust and the Juvenile Diabetes Research Foundation International. We gratefully acknowledge the participation of all of the patients, controls subjects, and family members and thank the Human Biological Data Interchange and Diabetes U.K. for U.S.A and U.K. multiplex families, respectively, Cristian Guja for the Romanian families, Dag Undlien for the Norwegian families and David Savage for the Northern Ireland families. GETIFIN (J. Tuomilehto, L. Kinnunen, E. Tuomilehto-Wolf, V. Harjutsalo and T. Valle) for the Finnish families and thank the Academy of Finland, the Sigrid Juselius Foundation and the JDRF for funding. We acknowledge use of DNA from the British 1958 Birth Cohort collection (Paul Burton, Richard Jones, Wendy McArdle, Marcus Pembrey, Susan Ring and David Strachan), funded by the Medical Research Council grant G0000934 and Wellcome Trust grant 068545/Z/02, and thank David Dunger and Barry Widmer for the type 1 diabetes case collection. DNA samples were prepared by Helen Stevens, Gillian Coleman, Trupti Mistry, Meeta Maisuria, Sarah Wood and Matthew Hardy. This study makes use of data generated by the Wellcome Trust Case Control Consortium. A full list of the investigators who contributed to the generation of the data is available from [57]. Funding for the project was provided by the Wellcome Trust under award 076113.

References

1. Wang WY, Barratt BJ, Clayton DG, Todd JA: **Genome-wide association studies: theoretical and practical concerns.** *Nat Rev Genet* 2005, **6**:109-118.
2. Cucca F, Lampis R, Congia M, Angius E, Nutland S, Bain SC, Barnett AH, Todd JA: **A correlation between the relative predisposition of MHC class II alleles to type 1 diabetes and the structure of their proteins.** *Hum Mol Genet* 2001, **10**:2025-2037.
3. Barratt BJ, Payne F, Lowe CE, Hermann R, Healy BC, Harold D, Concanon P, Gharani N, McCarthy MI, Olavesen MG, McCormack R, Guja C, Ionescu-Tirgoviste C, Undlien DE, Ronningen KS, Gillespie KM, Tuomilehto-Wolf E, Tuomilehto J, Bennett ST, Clayton DG, Cordell HJ, Todd JA: **Remapping the insulin gene/IDDM2 locus in type 1 diabetes.** *Diabetes* 2004, **53**:1884-1889.
4. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyanthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ronningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC: **Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.** *Nature* 2003, **423**:506-511.
5. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, MacMurray J, Meloni GF, Lucarelli P, Pellicchia M, Eisenbarth GS, Comings D, Mustelin T: **A functional variant of lymphoid tyrosine phosphatase is associated with type 1 diabetes.** *Nat Genet* 2004, **36**:337-338.
6. Smyth D, Cooper JD, Collins JE, Heward JM, Franklyn JA, Howson JM, Vella A, Nutland S, Rance HE, Maier L, Barratt BJ, Guja C, Ionescu-Tirgoviste C, Savage DA, Dunger DB, Widmer B, Strachan DP, Ring SM, Walker N, Clayton DG, Twells RC, Gough SC, Todd JA: **Repli-**

- cation of an association between the lymphoid tyrosine phosphatase locus (*LYP/PTPN22*) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. *Diabetes* 2004, **53**:3020-3023.
7. Vella A, Cooper JD, Lowe CE, Walker N, Nutland S, Widmer B, Jones R, Ring SM, McArdle W, Pembrey ME, Strachan DP, Dunger DB, Twells RC, Clayton DG, Todd JA: **Localization of a type 1 diabetes locus in the *IL2RA/CD25* region by use of tag single-nucleotide polymorphisms.** *Am J Hum Genet* 2005, **76**:773-779.
 8. Qu HQ, Montpetit A, Ge B, Hudson TJ, Polychronakos C: **Toward Further Mapping of the Association Between the *IL2RA* Locus and Type 1 Diabetes.** *Diabetes* 2007, **56**:1174-1176.
 9. Smyth DJ, Cooper JD, Bailey R, Field S, Burren O, Smink LJ, Guja C, Ionescu-Tirgoviste C, Widmer B, Dunger DB, Savage DA, Walker NM, Clayton DG, Todd JA: **A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (*IFIH1*) region.** *Nat Genet* 2006, **38**:617-619.
 10. **Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.** *Nature* 2007, **447**:661-678.
 11. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey R, Nejentsev S, Field SF, Payne F, Lowe CE, Szeszkó JS, Hafler JP, Zeitels L, Yang JH, Vella A, Nutland S, Stevens HE, Schuilenburg H, Coleman G, Mairuria M, Meadows W, Smink LJ, Healy B, Burren OS, Lam AA, Ovington NR, Allen J, Adlem E, Leung HT, Wallace C, Howson JM, Guja C, Ionescu-Tirgoviste C, Simmonds MJ, Heward JM, Gough SC, Dunger DB, Wicker LS, Clayton DG: **Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes.** *Nat Genet* 2007, **39**:857-864.
 12. Tait KF, Collins JE, Heward JM, Eaves I, Snook H, Franklin JA, Barnett AH, Todd JA, Maranian M, Compston A, Sawcer S, Gough SC: **Evidence for a Type 1 diabetes-specific mechanism for the insulin gene-associated *IDDM2* locus rather than a general influence on autoimmunity.** *Diabet Med* 2004, **21**:267-270.
 13. Smyth DJ, Howson JM, Payne F, Maier LM, Bailey R, Holland K, Lowe CE, Cooper JD, Hulme JS, Vella A, Dahlman I, Lam AC, Nutland S, Walker NM, Twells RC, Todd JA: **Analysis of polymorphisms in 16 genes in type 1 diabetes that have been associated with other immune-mediated diseases.** *BMC Med Genet* 2006, **7**:20.
 14. Tuomilehto J, Lounamaa R, Tuomilehto-Wolf E, Reunanen A, Virtala E, Kaprio EA, Akerblom HK: **Epidemiology of childhood diabetes mellitus in Finland – background of a nationwide study of type 1 (insulin-dependent) diabetes mellitus. The Childhood Diabetes in Finland (DiMe) Study Group.** *Diabetologia* 1992, **35**:70-76.
 15. Bain SC, Todd JA, Barnett AH: **The British Diabetic Association – Warren repository.** *Autoimmunity* 1990, **7**:83-85.
 16. Lernmark A: **Human cell lines from families available for diabetes research.** *Diabetologia* 1991, **34**:61.
 17. Patterson CC, Carson DJ, Hadden DR: **Epidemiology of childhood IDDM in Northern Ireland 1989–1994: low incidence in areas with highest population density and most household crowding. Northern Ireland Diabetes Study Group.** *Diabetologia* 1996, **39**:1063-1069.
 18. Undlien DE, Akselsen HE, Joner G, Dahl-Jorgensen K, Aagenaes O, Sovik O, Thorsby E, Ronningen KS: **No difference in the parental origin of susceptibility HLA class II haplotypes among Norwegian patients with insulin-dependent diabetes mellitus.** *Am J Hum Genet* 1995, **57**:1511-1514.
 19. Ionescu-Tirgoviste C, Guja C, Herr M, Cucca E, Welsh K, Bunce M, Marshall S, Todd JA: **Low frequency of HLA DRB1*03 – DQB1*02 and DQB1*0302 haplotypes in Romania is consistent with the country's low incidence of Type 1 diabetes.** *Diabetologia* 2001, **44**(Suppl 3):B60-66.
 20. Cases TD: [<http://www-gene.cimr.cam.ac.uk/ucdr/grid.shtml>].
 21. Power C, Elliott J: **Cohort profile: 1958 British birth cohort (National Child Development Study).** *Int J Epidemiol* 2006, **35**:34-41.
 22. SeattleSNPs: [<http://pga.mbt.washington.edu>].
 23. Morahan G, Huang D, Wu M, Holt BJ, White GP, Kendall GE, Sly PD, Holt PG: **Association of *IL12B* promoter polymorphism with severity of atopic and non-atopic asthma in children.** *Lancet* 2002, **360**:455-459.
 24. Barrett JC, Fry B, Maller J, Daly MJ: **Haploview: analysis and visualization of LD and haplotype maps.** *Bioinformatics* 2005, **21**:263-265.
 25. **The International HapMap Project.** *Nature* 2003, **426**:789-796.
 26. Wang N, Akey JM, Zhang K, Chakraborty R, Jin L: **Distribution of recombination crossovers and the origin of haplotype blocks: the interplay of population history, recombination, and mutation.** *Am J Hum Genet* 2002, **71**:1227-1234.
 27. Clayton DG, Walker NM, Smyth DJ, Pask R, Cooper JD, Maier LM, Smink LJ, Lam AC, Ovington NR, Stevens HE, Nutland S, Howson JM, Faham M, Moorhead M, Jones HB, Falkowski M, Hardenbol P, Willis TD, Todd JA: **Population structure, differential bias and genomic control in a large-scale, case-control association study.** *Nat Genet* 2005, **37**:1243-1246.
 28. Stata: [<http://www.stata.com/>].
 29. R: [<http://www.r-project.org/>].
 30. Additional routines: [<http://www-gene.cimr.cam.ac.uk/clayton/software/>].
 31. Spielman RS, Ewens WJ: **The TDT and other family-based tests for linkage disequilibrium and association.** *Am J Hum Genet* 1996, **59**:983-989.
 32. Cordell HJ, Clayton DG: **A unified stepwise regression procedure for evaluating the relative effects of polymorphisms within a gene using case/control or family data: application to HLA in type 1 diabetes.** *Am J Hum Genet* 2002, **70**:124-141.
 33. Chapman JM, Cooper JD, Todd JA, Clayton DG: **Detecting disease associations due to linkage disequilibrium using haplotype tags: a class of tests and the determinants of statistical power.** *Hum Hered* 2003, **56**:18-31.
 34. Lowe CE, Cooper JD, Chapman JM, Barratt BJ, Twells RC, Green EA, Savage DA, Guja C, Ionescu-Tirgoviste C, Tuomilehto-Wolf E, Tuomilehto J, Todd JA, Clayton DG: **Cost-effective analysis of candidate genes using htSNPs: a staged approach.** *Genes Immun* 2004, **5**:301-305.
 35. Chistiakov DA, Chernisheva A, Savost'yanov KV, Turakulov RI, Kuraeva TL, Dedov II, Nosikov VV: **The *TAF5L* gene on chromosome 1q42 is associated with type 1 diabetes in Russian affected patients.** *Autoimmunity* 2005, **38**:283-293.
 36. Nielsen C, Hansen D, Husby S, Jacobsen BB, Lillevang ST: **Association of a putative regulatory polymorphism in the *PD-1* gene with susceptibility to type 1 diabetes.** *Tissue Antigens* 2003, **62**:492-497.
 37. Prokunina L, Padyukov L, Bannett A, de Faire U, Wiman B, Prince J, Alfredsson L, Klareskog L, Alarcon-Riquelme M: **Association of the *PD-1.3A* allele of the *PDCD1* gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope.** *Arthritis Rheum* 2004, **50**:1770-1773.
 38. Noble JA, White AM, Lazzaroni LC, Valdes AM, Mirel DB, Reynolds R, Grupe A, Aud D, Peltz G, Erlich HA: **A polymorphism in the *TCF7* gene, *C883A*, is associated with type 1 diabetes.** *Diabetes* 2003, **52**:1579-1582.
 39. Ladner MB, Bottini N, Valdes AM, Noble JA: **Association of the single nucleotide polymorphism *C1858T* of the *PTPN22* gene with type 1 diabetes.** *Hum Immunol* 2005, **66**:60-64.
 40. Windsor L, Morahan G, Huang D, McCann V, Jones T, James I, Christiansen FT, Price P: **Alleles of the *IL12B* 3'UTR associate with late onset of type 1 diabetes.** *Hum Immunol* 2004, **65**:1432-1436.
 41. Davoudi-Semiromi A, Yang JJ, She JX: ***IL-12p40* is associated with type 1 diabetes in Caucasian-American families.** *Diabetes* 2002, **51**:2334-2336.
 42. Khoo SK, Hayden CM, Roberts M, Horak E, de Klerk N, Zhang G, Robertson CF, Goldblatt J, Le Souef P: **Associations of the *IL12B* promoter polymorphism in longitudinal data from asthmatic patients 7 to 42 years of age.** *J Allergy Clin Immunol* 2004, **113**:475-481.
 43. Kristiansen OP, Nolsoe RL, Larsen L, Gjesing AM, Johannesen J, Larsen ZM, Lykkesfeldt AE, Karlsen AE, Pociot F, Mandrup-Poulsen T: **Association of a functional 17beta-estradiol sensitive *IL6-174G/C* promoter polymorphism with early-onset type 1 diabetes in females.** *Hum Mol Genet* 2003, **12**:1101-1110.
 44. Gillespie KM, Nolsoe R, Betin VM, Kristiansen OP, Bingley PJ, Mandrup-Poulsen T, Gale EA: **Is puberty an accelerator of type 1 diabetes in *IL6-174CC* females?** *Diabetes* 2005, **54**:1245-1248.
 45. Kristiansen OP, Nolsoe RL, Holst H, Reker S, Larsen ZM, Johannesen J, Nerup J, Pociot F, Mandrup-Poulsen T: **The intercellular adhe-**

- sion molecule-1 K469E polymorphism in type 1 diabetes. *Immunogenetics* 2000, **52**:107-111.
46. Sasaki Y, Ihara K, Matsuura N, Kohno H, Nagafuchi S, Kuromaru R, Kusuhara K, Takeya R, Hoey T, Sumimoto H, Hara T: **Identification of a novel type 1 diabetes susceptibility gene, T-bet.** *Hum Genet* 2004, **115**:177-184.
 47. Chung HT, Kim LH, Park BL, Lee JH, Park HS, Choi BW, Hong SJ, Chae SC, Kim JJ, Park CS, Shin HD: **Association analysis of novel TBX21 variants with asthma phenotypes.** *Hum Mutat* 2003, **22**:257.
 48. Tomer Y, Concepcion E, Greenberg DA: **A C/T single-nucleotide polymorphism in the region of the CD40 gene is associated with Graves' disease.** *Thyroid* 2002, **12**:1129-1135.
 49. Morahan G, Huang D, Ymer SJ, Cancilla MR, Stephen K, Dabadghao P, Werther G, Tait BD, Harrison LC, Colman PG: **Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele.** *Nat Genet* 2001, **27**:218-221.
 50. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N: **Assessing the probability that a positive report is false: an approach for molecular epidemiology studies.** *J Natl Cancer Inst* 2004, **96**:434-442.
 51. Onengut-Gumuscu S, Ewens KG, Spielman RS, Concannon P: **A functional polymorphism (1858C/T) in the PTPN22 gene is linked and associated with type 1 diabetes in multiplex families.** *Genes Immun* 2004, **5**:678-680.
 52. Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, Kern M, Moser KL, Begovich AB, Carlton VE, Li W, Lee AT, Ortmann W, Behrens TW, Gregersen PK: **Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes.** *Am J Hum Genet* 2005, **76**:561-571.
 53. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, Roberts RG, Nimmo ER, Cummings FR, Soars D, Drummond H, Lees CW, Khawaja SA, Bagnall R, Burke DA, Toddhunter CE, Ahmad T, Onnie CM, McArdle W, Strachan D, Bethel G, Bryan C, Lewis CM, Deloukas P, Forbes A, Sanderson J, Jewell DP, Satsangi J, Mansfield JC, Cardon L, Mathew CG: **Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility.** *Nat Genet* 2007, **39**:830-832.
 54. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese JJ, Leong DU, Panko JM, McAllister LB, Hansen CB, Papenfuss J, Prescott SM, White TJ, Lepert MF, Krueger GG, Begovich AB: **A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.** *Am J Hum Genet* 2007, **80**:273-290.
 55. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, Perry JR, Rayner NW, Freathy RM, Barrett JC, Shields B, Morris AP, Ellard S, Groves CJ, Harries LW, Marchini JL, Owen KR, Knight B, Cardon LR, Walker M, Hitman GA, Morris AD, Doney AS, Burton PR, Clayton DG, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP, Ouwehand WH, Samani NJ, Todd JA, Donnelly P, Davison D, Easton D, Evans D, Leung HT, Spencer CC, Tobin MD, Attwood AP, Boorman JP, Cant B, Everson U, Hussey JM, Jolley JD, Knight AS, Koch K, Meech E, Nutland S, Prowse CV, Stevens HE, Taylor NC, Walters GR, Walker NM, Watkins NA, Winzer T, Jones RW, McArdle WL, Ring SM, Strachan DP, Pembrey M, Breen G, St Clair D, Caesar S, Gordon-Smith K, Jones L, Fraser C, Green EK, Grozeva D, Hamshere ML, Holmans PA, Jones IR, Kirov G, Moskvina V, Nikolov I, O'Donovan MC, Owen MJ, Collier DA, Elkin A, Farmer A, Williamson R, McGuffin P, Young AH, Ferrier IN, Ball SG, Balmforth AJ, Barrett JH, Bishop DT, Iles MM, Maqbool A, Yuldasheva N, Hall AS, Braund PS, Dixon RJ, Mangino M, Stevens S, Thompson JR, Bredin F, Tremelling M, et al.: **Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes.** *Science* 2007, **316**:1336-1341.
 56. Howson JM, Dunger DB, Nutland S, Stevens H, Wicker LS, Todd JA: **A type 1 diabetes subgroup with a female bias is characterised by failure in tolerance to thyroid peroxidase at an early age and a strong association with the cytotoxic T-lymphocyte-associated antigen-4 gene.** *Diabetologia* 2007, **50**:741-746.
 57. WTCCC: [<http://www.wtccc.org.uk>].
 58. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, Brookes AJ, Tentler D, Kristjansdottir H, Grondal G, Bolstad AI, Svenungsson E, Lundberg I, Sturfelt G, Jonsson A, Truedsson L, Lima G, Alcocer-Varela J, Jonsson R, Gyllenstein UB, Harley JB, Alarcon-Segovia D, Steinsson K, Alarcon-Riquelme ME: **A regulatory polymorphism in PDCDI is associated with susceptibility to systemic lupus erythematosus in humans.** *Nat Genet* 2002, **32**:666-669.
 59. Lin SC, Yen JH, Tsai JJ, Tsai WC, Ou TT, Liu HW, Chen CJ: **Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus.** *Arthritis Rheum* 2004, **50**:770-775.
 60. Dahlman I, Eaves IA, Kosoy R, Morrison VA, Heward J, Gough SC, Allahabadi A, Franklyn JA, Tuomilehto J, Tuomilehto-Wolf E, Cucca F, Guja C, Ionescu-Tirgoviste C, Stevens H, Carr P, Nutland S, McKinney P, Shield JP, Wang W, Cordell HJ, Walker N, Todd JA, Concannon P: **Parameters for reliable results in genetic association studies in common disease.** *Nat Genet* 2002, **30**:149-150.
 61. McCormack RM, Maxwell AP, Carson DJ, Patterson CC, Middleton D, Savage DA: **The IL12B 3' untranslated region DNA polymorphism is not associated with early-onset type 1 diabetes.** *Genes Immun* 2002, **3**:433-435.
 62. Nistico L, Giorgi G, Giordano M, Galgani A, Petrone A, D'Alfonso S, Federici M, Di Mario U, Pozzilli P, Buzzetti R, Cascino I: **IL12B polymorphism and type 1 diabetes in the Italian population: a case-control study.** *Diabetes* 2002, **51**:1649-1650.
 63. Bergholdt R, Ghandil P, Johannesen J, Kristiansen OP, Kockum I, Luthman H, Ronningen KS, Nerup J, Julier C, Pociot F: **Genetic and functional evaluation of an interleukin-12 polymorphism (IDDM18) in families with type 1 diabetes.** *J Med Genet* 2004, **41**:e39.
 64. Johansson S, Lie BA, Thorsby E, Undlien DE: **The polymorphism in the 3' untranslated region of IL12B has a negligible effect on the susceptibility to develop type 1 diabetes in Norway.** *Immunogenetics* 2001, **53**:603-605.
 65. Jahromi MM, Millward BA, Demaine AG: **A polymorphism in the promoter region of the gene for interleukin-6 is associated with susceptibility to type 1 diabetes mellitus.** *J Interferon Cytokine Res* 2000, **20**:885-888.
 66. Eerligh P, Koeleman BP, Dudbridge F, Jan Bruining G, Roep BO, Giphart MJ: **Functional genetic polymorphisms in cytokines and metabolic genes as additional genetic markers for susceptibility to develop type 1 diabetes.** *Genes Immun* 2004, **5**:36-40.
 67. Nejentsev S, Guja C, McCormack R, Cooper J, Howson JM, Nutland S, Rance H, Walker N, Undlien D, Ronningen KS, Tuomilehto-Wolf E, Tuomilehto J, Ionescu-Tirgoviste C, Gale EA, Bingley PJ, Gillespie KM, Savage DA, Carson DJ, Patterson CC, Maxwell AP, Todd JA: **Association of intercellular adhesion molecule-1 gene with type 1 diabetes.** *Lancet* 2003, **362**:1723-1724.
 68. Ma J, Mollsten A, Prazny M, Falhammar H, Brismar K, Dahlquist G, Efendic S, Gu HF: **Genetic influences of the intercellular adhesion molecule 1 (ICAM-1) gene polymorphisms in development of Type 1 diabetes and diabetic nephropathy.** *Diabet Med* 2006, **23**:1093-1099.
 69. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhardt AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee A, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH: **A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene.** *Science* 2006.
 70. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G, Jonsen A, Rantapaa-Dahlqvist S, Moller B, Kere J, Koskenmies S, Widen E, Eloranta ML, Julkunen H, Kristjansdottir H, Steinsson K, Alm G, Ronnblom L, Syvanen AC: **Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus.** *Am J Hum Genet* 2005, **76**:528-537.
 71. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, Gonzalez Escribano MF, Pons-Estel B, Petri M, Daly M, Gregersen PK, Martin J, Altschuler D, Behrens TW, Alarcon-Riquelme ME: **A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus.** *Nat Genet* 2006, **38**:550-555.
 72. Qu HQ, Marchand L, Grabs R, Polychronakos C: **The IRF5 polymorphism in type 1 diabetes.** *J Med Genet* 2007, **44**:670-672.
 73. Kim TY, Park YJ, Hwang JK, Song JY, Park KS, Cho BY, Park DJ: **A C/T polymorphism in the 5'-untranslated region of the CD40**

gene is associated with Graves' disease in Koreans. *Thyroid* 2003, **13**:919-925.

74. Mukai T, Hiromatsu Y, Fukutani T, Ichimura M, Kaku H, Miyake I, Yamada K: **A C/T polymorphism in the 5' untranslated region of the CD40 gene is associated with later onset of Graves' disease in Japanese.** *Endocr J* 2005, **52**:471-477.
75. Houston FA, Wilson V, Jennings CE, Owen CJ, Donaldson P, Perros P, Pearce SH: **Role of the CD40 locus in Graves' disease.** *Thyroid* 2004, **14**:506-509.
76. Heward JM, Simmonds MJ, Carr-Smith J, Foxall H, Franklyn JA, Gough SC: **A single nucleotide polymorphism in the CD40 gene on chromosome 20q (GD-2) provides no evidence for susceptibility to Graves' disease in UK Caucasians.** *Clin Endocrinol (Oxf)* 2004, **61**:269-272.

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2350/8/71/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

